NeurologyLive Friday 5 — February 12, 2021

February 12, 2021
NeurologyLive Staff

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 12, 2021.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Clinically Meaningful Migraine Prevention: Richard B. Lipton, MD

The director of the Montefiore Headache Center discussed how rimegepant was observed to produce clinically meaningful improvements in migraine prevention.

2: Mind Moments Episode 29: Seizure Action Plan

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive conversation with Scott Perry, MD, co-director, Jane and John Justin Neurosciences Center, Cook Children’s Hospital; Orrin Devinksy, MD, director, Comprehensive Epilepsy Center, NYU Langone; and Tracy Salazar, PhD, executive director, Lennox-Gastaut Syndrome Foundation.

3: Investigating Disability and Onset Age in NMOSD: Gabrielle Macaron, MD

The neurologist from Cleveland Clinic discussed how her study reinforced previous findings that individuals with early-onset neuromyelitis optica spectrum disorders are more likely to experience severe vision loss.

4: NeuroVoices: Lea Davis, PhD, and Slavina Goleva, on Epidemiology of Functional Seizures

The duo from Vanderbilt University shared the background on their recently published study that found novel associations between functional seizures, cerebrovascular disease, and other psychiatric disorders.

5: Understanding Why Costs Are Soaring for SMA Management

The primary investigator of RESPOND discussed the trial’s goals and measures, as well as insight into why clinical trials like it are important in spinal muscular atrophy.

NeurologyLive Wants Your Feedback!

We kindly ask you to share 5 minutes of your time with us, in order to help us better craft our content to meet your needs and interests.